Skip Main Navigation
Page Content
This event has ended

Connecticut Synthetic Chemistry Start-Up Uses a Practical Business Model to Develop Drugs

Bioscience ClubhouseCT

Wednesday, September 24, 2014 from 4:00 PM to 5:30 PM (EDT)

Connecticut Synthetic Chemistry Start-Up Uses a...

Ticket Information

Ticket Type Sales End Price Fee Quantity
General Admission
Ticket prices will be used to cover event costs. Please note that Eventbrite charges a handling fee in addition to the amount paid.
Ended $15.00 $1.74
Students Ended Free $0.00
Donation
Donations will only be used to cover event costs. Please note that Eventbrite charges a handling fee in addition to the amount donated.
Ended

Who's Going

Loading your connections...

Share Connecticut Synthetic Chemistry Start-Up Uses a Practical Business Model to Develop Drugs

Event Details

As a chemistry service focused company, Cheminpharma LLC applies a non-traditional business model of using revenues generated from their business to fund novel preclinical candidates. Cheminpharma designed and synthesized a novel macrocyclic inhibitor CIP-137401, which has the potential to be a lead candidate for the orphan disease LMNA mutated cardiomyopathy and a variety of cancers arising from mutations in the Ras pathway. 

Allomek Therapeutics, a spin-off company from Cheminpharma was established to focus on developing CIP-137401. As a UCONN Technology Incubation Program (TIP) Incubator company, Allomek has received pre-seed funding from Connecticut Innovations and was also awarded phase-I STTR in collaboration with Columbia University. Both Cheminpharma and Allomek were nominated the “Most Promising Life Science Product” by CT Technology Council. 

Uday Khire, Founder, CEO of Cheminparma LLC and Cofounder of Allomek Therapeutics, will share his experience managing two very different business operations, establishing funding for R&D, and his vision for the businesses. 

CURE and BioscienceClubhouseCT recognize the generous support of the sponsors of this program:


About the Speaker

Uday Khire, Ph.D. MBA, a synthetic chemist with over 17 years of experience in medicinal chemistry/drug discovery. He worked as a medicinal chemist on numerous preclinical drug discovery projects in the therapeutic areas of diabetes, obesity and oncology at Bayer Research Center (BRC) in West Haven. Uday is a co-inventor of a novel multi-kinase inhibitor, developed jointly by Bayer and Onyx and is approved as first line therapy for kidney and liver cancer in US and other major markets. He has authored numerous peer-reviewed international scientific publications and is inventor of many patents/patent applications.


Sponsors 

    

Have questions about Connecticut Synthetic Chemistry Start-Up Uses a Practical Business Model to Develop Drugs? Contact Bioscience ClubhouseCT

When & Where


The Study at Yale
1157 Chapel St
New Haven, CT 06510

Wednesday, September 24, 2014 from 4:00 PM to 5:30 PM (EDT)


  Add to my calendar

Organizer

Bioscience ClubhouseCT

The Bioscience ClubhouseCT is led by CURE and is a statewide program, founded in 2013 by the Economic Development Corporation of New Haven. At the Bioscience ClubhouseCT our mission is to help passionate entrepreneurs seeking to create sustainable science-based companies in CT. The Bioscience ClubhouseCT provides a forum for cultivating and retaining talent, building connectivity, accessing resources, creating a vibrant virtual and physical life and healthcare sciences community, and sharing the success stories and learnings of CT entrepreneurs. Together we are establishing a critical mass of science-based companies in Connecticut.

  Contact the Organizer

Please log in or sign up

In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.